1.946 USD
+0.08 (+4.06%)
We assign a fundamental rating of 3 out of 10 to CLGN. CLGN was compared to 525 industry peers in the Biotechnology industry. While CLGN seems to be doing ok healthwise, there are quite some concerns on its profitability. While showing a medium growth rate, CLGN is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
- In the past year CLGN has reported negative net income.
- CLGN had a negative operating cash flow in the past year.
- CLGN had negative earnings in 4 of the past 5 years.
- In the past 5 years CLGN reported 4 times negative operating cash flow.
1.2 Ratios
- The Return On Assets of CLGN (-86.31%) is worse than 71.24% of its industry peers.
- With a Return On Equity value of -130.68%, CLGN is not doing good in the industry: 61.90% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -86.31% | ||
| ROE | -130.68% | ||
| ROIC | N/A |
ROA(3y)-51.39%
ROA(5y)-41.38%
ROE(3y)-66.85%
ROE(5y)-65.77%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- Looking at the Gross Margin, with a value of 63.03%, CLGN is in the better half of the industry, outperforming 79.05% of the companies in the same industry.
- The Profit Margin and Operating Margin are not available for CLGN so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 63.03% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- CLGN does not have a ROIC to compare to the WACC, probably because it is not profitable.
- The number of shares outstanding for CLGN remains at a similar level compared to 1 year ago.
- Compared to 5 years ago, CLGN has more shares outstanding
- There is no outstanding debt for CLGN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
- Based on the Altman-Z score of -11.20, we must say that CLGN is in the distress zone and has some risk of bankruptcy.
- CLGN has a worse Altman-Z score (-11.20) than 73.90% of its industry peers.
- CLGN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -11.2 |
ROIC/WACCN/A
WACC8.73%
2.3 Liquidity
- A Current Ratio of 3.66 indicates that CLGN has no problem at all paying its short term obligations.
- CLGN has a Current ratio (3.66) which is comparable to the rest of the industry.
- A Quick Ratio of 3.45 indicates that CLGN has no problem at all paying its short term obligations.
- With a Quick ratio value of 3.45, CLGN perfoms like the industry average, outperforming 43.81% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.66 | ||
| Quick Ratio | 3.45 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an impressive 25.00% over the past year.
- The Revenue has grown by 280.77% in the past year. This is a very strong growth!
- CLGN shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -25.99% yearly.
EPS 1Y (TTM)25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%28.95%
Revenue 1Y (TTM)280.77%
Revenue growth 3Y-67.95%
Revenue growth 5Y-25.99%
Sales Q2Q%1825%
3.2 Future
- Based on estimates for the next years, CLGN will show a very strong growth in Earnings Per Share. The EPS will grow by 25.70% on average per year.
- Based on estimates for the next years, CLGN will show a very strong growth in Revenue. The Revenue will grow by 103.99% on average per year.
EPS Next Y77.99%
EPS Next 2Y40.31%
EPS Next 3Y25.7%
EPS Next 5YN/A
Revenue Next Year422.12%
Revenue Next 2Y211.49%
Revenue Next 3Y103.99%
Revenue Next 5YN/A
3.3 Evolution
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for CLGN. In the last year negative earnings were reported.
- Also next year CLGN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- A more expensive valuation may be justified as CLGN's earnings are expected to grow with 25.70% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.31%
EPS Next 3Y25.7%
5. Dividend
5.1 Amount
- No dividends for CLGN!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
COLLPLANT BIOTECHNOLOGIES LT / CLGN FAQ
What is the fundamental rating for CLGN stock?
ChartMill assigns a fundamental rating of 3 / 10 to CLGN.
What is the valuation status for CLGN stock?
ChartMill assigns a valuation rating of 1 / 10 to COLLPLANT BIOTECHNOLOGIES LT (CLGN). This can be considered as Overvalued.
Can you provide the profitability details for COLLPLANT BIOTECHNOLOGIES LT?
COLLPLANT BIOTECHNOLOGIES LT (CLGN) has a profitability rating of 1 / 10.
What is the expected EPS growth for COLLPLANT BIOTECHNOLOGIES LT (CLGN) stock?
The Earnings per Share (EPS) of COLLPLANT BIOTECHNOLOGIES LT (CLGN) is expected to grow by 77.99% in the next year.